Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
In-Depth Review
You have accessRestricted Access

Clinical Consequences of Mutations in Sodium Phosphate Cotransporters

Eleanor Lederer and Ken-ichi Miyamoto
CJASN July 2012, 7 (7) 1179-1187; DOI: https://doi.org/10.2215/CJN.09090911
Eleanor Lederer
*Robley Rex Veterans Affairs Medical Center and
†University of Louisville School of Medicine, Louisville, Kentucky; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken-ichi Miyamoto
‡Institution of Health Biosciences, University of Tokushima, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Summary

Three families of sodium phosphate cotransporters have been described. Their specific roles in human health and disease have not been defined. Review of the literature reveals that the type II sodium phosphate cotransporters play a significant role in transepithelial transport in a number of tissues including kidney, intestine, salivary gland, mammary gland, and lung. The type I transporters seem to play a major role in renal urate handling and mutations in these proteins have been implicated in susceptibility to gout. The ubiquitously expressed type III transporters play a lesser role in phosphate homeostasis but contribute to cellular phosphate uptake, mineralization, and inflammation. The recognition of species differences in the expression, regulation, and function of these transport proteins suggests an urgent need to find ways to study them in humans.

Introduction

The roles of sodium phosphate cotransporter functions in human clinical physiology and disease processes have not been defined. In addition to maintaining phosphate homeostasis through facilitation of transepithelial transport and ensuring adequacy of intracellular phosphate stores, sodium-dependent phosphate transporters play a role in the transport of a number of other substances and have functions ostensibly unrelated to phosphate transport. Three families of sodium phosphate cotransporters have been identified, each with multiple members (1) (Table 1). They are all intrinsic membrane proteins exhibiting multiple membrane-spanning domains.

View this table:
  • View inline
  • View popup
Table 1.

Distribution of sodium phosphate cotransporters

The aims of this review are to provide the audience with an updated inventory of identified sodium phosphate cotransporters (Table 2), to compare the human and animal syndromes associated with mutation or loss of each transporter, and to highlight the gaps in our understanding of the roles that these transporters play in human phosphate physiology and pathophysiology (Figure 1 and Table 3).

View this table:
  • View inline
  • View popup
Table 2.

Functions of sodium phosphate cotransporters

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Distribution of phosphate transporters and diseases associated with dysregulation/dysfunction. This figure depicts the locations for sodium phosphate cotransporters identified in human organs (transporter underlined). Diseases associated with dysregulation or dysfunction of the transporter are listed under the transporter. Proposed but not identified disease associations are indicated by a question mark (?).

View this table:
  • View inline
  • View popup
Table 3.

Comparison of human and murine phenotypes for sodium phosphate cotransporter deficiency

Type I Sodium Phosphate Cotransporters

Npt1

Npt1 (NaPi-1, SLC17A1) was the first sodium phosphate cotransporter isolated in the early 1990s from a rabbit renal cortex library (2), followed shortly afterward by the human and mouse homologs (3–5). Immunohistochemical studies confirmed Npt1 localization to the renal proximal tubule, the site of regulated phosphate transport; however, the relatively low affinity of the transporter for phosphate and the lack of regulation by parathyroid hormone or ambient Pi suggested that phosphate was not the major transport substrate for this protein (6). Subsequent studies confirmed that Npt1 transported a variety of organic and inorganic anions more readily than phosphate (7–9).

The physiologic role for Npt1 remained largely unexplored until the recent description of several patients with gout who exhibit decreased proximal tubule uric acid secretion associated with specific Npt1 polymorphisms (10–14). Npt1 has also been identified in liver, where it is felt to play a role in organic anion transport in hepatic sinusoids (15). Although not regarded as a major contributor to phosphate homeostasis, proximal tubule Npt1 expression is upregulated in animal models of deficient Npt2 transporter expression, suggesting a role for this transporter under some extreme circumstances (16).

Npt4

Npt4 (SLC17A3), an anion transporter with significant homology to Npt1, also seems to play a role in urate transport in the kidney. Several studies have demonstrated an association between Npt4 single nucleotide polymorphisms and uric acid concentration in the serum and gout (17–20). Npt4 interacts with diuretics such as furosemide and bumetanide, suggesting that it may be responsible for the renal proximal tubule secretion of diuretics (21). Although Npt4 has also been identified in liver cells as a microsomal phosphate transporter (22), Npt4 is not felt to play a significant role in phosphate homeostasis.

Type II Sodium Phosphate Cotransporters

Npt2a

Npt2a (NaPi-IIa, SLC34A1 [Napi-2, 3, 4, 5, 6, 7]) (23–27), the first identified member of the family of type II sodium phosphate cotransporters, is expressed predominantly on proximal renal tubule apical membrane and on osteoclast basolateral membrane (23–30). A substantial body of work suggests that it is the major regulated sodium phosphate cotransporter responsible for proximal tubule phosphate reabsorption (31–36). In rodents, Npt2a is estimated to be responsible for >70% of proximal tubule phosphate reabsorption. Npt2a mRNA is at relatively low abundance at birth in mice but is markedly upregulated to adult levels during the first 2 weeks of life (37). Protein expression follows the mRNA expression peaking at 21 days of life and is dependent on expression of the vitamin D receptor (VDR) (38). Regulation of 1α hydroxylase by phosphate is not dependent on Npt2a expression (39). Provision of a high-phosphate diet to the VDR-null mice restores renal Npt2a expression to wild-type levels, suggesting the presence of a gut–kidney interaction in the neonatal period required for normal Npt2a expression, mediated by phosphate but likely facilitated by the VDR through its ability to enhance intestinal phosphate absorption (38). Studies of Npt2a expression in human tissue mirror the findings in mice, Npt2a expression occurring relatively late in development, peaking in the postnatal period, and then progressively falling with age (40).

Several human disease processes involving abnormal regulation of renal phosphate homeostasis have been described. X-linked hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, and oncogenic osteomalacia are characterized by low serum phosphate accompanied by inappropriate phosphaturia and osteomalacia (41). Studies in humans and animal models of these disorders have identified the presence of circulating substances, such as fibroblast growth factor 23 (FGF23), that decrease proximal tubule phosphate reabsorption producing phosphaturia (42–46). Although human renal Npt2a expression has not been examined directly, serum from patients afflicted with these disorders decreases phosphate transport and Npt2a expression in cultured proximal tubule cell lines, suggesting a similar in vivo phenomenon. Conversely, decreased FGF23/Klotho activity as seen with loss-of-function mutations in FGF23 or GALNT3, the enzyme responsible for O-glycosylation of FGF23, results in hyperphosphatemic tumoral calcinosis, characterized by hyperphosphatemia, decreased renal phosphate excretion, and extraskeletal calcifications (47–49). As for the phosphaturic syndromes, no studies have actually examined the renal expression of Npt2a in human participants with tumoral calcinosis.

A potential role for abnormal bone Npt2a expression or function in the clinical manifestations of these human diseases has been suggested but has not been directly tested. Npt2a and Npt2b are co-expressed in mineralization and upregulated before matrix mineralization and in the presence of high phosphate (50). Npt2a null adult mice do not exhibit bone findings consistent with human rickets (32,51,52), and adequate dietary phosphate ameliorates the bone mineralization defect in human hereditary rickets and the Npt2a null mouse. These findings suggest that the bone features of X-linked and autosomal dominant hypophosphatemic rickets result predominantly from defective renal Npt2a function. Mutations in Npt2a itself leading to human disease have rarely been described. Prié et al. (53) identified sequence variants in the Npt2a gene in 2 of 20 patients with hypophosphatemia, nephrolithiasis, and/or osteoporosis. Phosphate uptake in Xenopus oocytes expressing the genes of these two patients was decreased, suggesting a role for abnormal Npt2a function in nephrolithiasis and osteoporosis. Comparison of renal phosphate handling in >200 calcium stone formers compared with normal controls showed that the mean tubular maximum for phosphate (TmPi) in the stone formers was significantly less than in those who did not form stones. In contrast, Lapointe et al. (54) were unable to show similar changes in Npt2a-mediated phosphate transport even in cases in which significant sequence variants in the coding region of Npt2a were identified.

Mice deficient in Npt2a exhibit hypercalciuria, nephrocalcinosis, and kidney stone formation (32). The presumed pathogenesis for nephrocalcinosis and nephrolithiasis in the Npt2a null mouse is stimulation of 1,25 vitamin D production by hypophosphatemia, resulting in enhanced intestinal calcium absorption and subsequent hypercalciuria. Mice lacking Npt2a function show a high incidence of intratubular calcium phosphate crystals within the first month of life that diminish with age and interstitial calcium phosphate deposits that do not disappear with aging (55–59). The calcium deposits in the Npt2a-deficient mice are predominantly in the cortex and outer medulla, in contrast to human nephrocalcinosis associated with stone formation that generally occurs in the medulla and papilla.

In 2010, Magen et al. (60,61) described a homozygous Npt2a mutation with loss of function in two offspring of a consanguineous union who exhibited autosomal recessive Fanconi syndrome and hypophosphatemic rickets. Xenopus oocytes and opossum kidney cells expressing the mutated Npt2a showed decreased phosphate transport due to faulty trafficking of the transporter to the apical membrane. The affected individuals showed elevated 1,25 vitamin D levels and hypercalciuria during childhood that resolved by adulthood, attributed to the development of nutritional vitamin D deficiency. The authors suggested that accumulation of protein within the cell exerted toxic effects leading to Fanconi syndrome. An alternative explanation is that Npt2a-mediated phosphate transport is critical for maintenance of normal proximal tubule function through provision of adequate intracellular phosphate. The global loss of transport function in these individuals is reminiscent of the demonstration by Brazy et al. (62) of the marked decrease in fluid transport seen in proximal tubules perfused with phosphate-free medium.

Notable differences between human and murine loss of Npt2a function stand out. Nephrocalcinosis and stone formation are seen in Npt2a knockout mice but not the human participants lacking Npt2a function. Fanconi syndrome is seen in the human participants but not the Npt2a null mouse. Skeletal abnormalities are transient in the Npt2a null mouse but severe and persistent in patients with phosphaturic syndromes such as X-linked hypophosphatemic rickets and oncogenic osteomalacia. The reasons for these contrasting phenotypic features are unknown and emphasize the need for direct studies of Npt2a in human participants. It may be that in humans, Npt2a plays a lesser role in renal phosphate transport than in mice. Alternatively, the role of Npt2a in maintenance of bone homeostasis may differ between the two species.

Of perhaps greater interest are newer genome-wide association studies showing an association between Npt2a variants, serum phosphate level, and the development of CKD (63,64). These studies not only reaffirm the importance of Npt2a in human phosphate homeostasis but suggest a more central role for phosphate homeostasis in cardiovascular health because several studies have now correlated serum phosphate level with cardiovascular morbidity and mortality, as reviewed by Kendrick et al. (65). The link between serum phosphate and cardiovascular disease has not been defined but could involve a number of mechanisms including regulation of FGF23, Klotho, or vascular calcification and/or remodeling.

Npt2b

Compared with Npt2a, Npt2b (NaPi-IIb, SLC34A2) has a much broader range of organ expression. Initially described by Hilfiker et al. in the mouse small intestine, the protein shows substantial homology (57%–70%) but significant divergence from Npt2a (66). Immunohistochemical studies in mice have identified Npt2b protein in small intestine, lung in type II alveolar cells, salivary duct cells, mammary duct cells, epididymis, and liver cells (67–70). The Npt2b knockout is lethal, with embryonic death at midgestation (71). Conditional and tissue-specific knockouts have confirmed a significant role for Npt2b in intestinal phosphate transport (72). Absence of the protein results in a 50% reduction in intestinal phosphate absorption and a compensatory reduction in renal phosphate excretion accompanied by an increase in renal proximal tubule Npt2a expression. Animal studies have also suggested roles for regulated Npt2b expression in surfactant production, male fertility, biliary phosphate concentration, and odontogenesis.

The mRNA for Npt2b has been identified in small intestine, kidney, lymphoid tissue, lung, placenta, uterus, prostate, testis, liver, pancreas, thyroid, salivary gland, and multiple fetal tissues (73–75). Individuals with homozygous Npt2b loss-of-function mutations develop pulmonary alveolar microlithiasis (76,77), an unusual disorder characterized by the development of respiratory failure accompanied by alveolar calcifications in middle age. Some patients exhibit calcifications in a number of other organs in which Npt2b mRNA has been identified, including kidneys, pleura, seminal vesicles, urethra, and gall bladder. Whether these individuals exhibit diminished intestinal phosphate absorption has not been explicitly studied. Corut et al. (76) stated that investigation of one of their affected individuals showed 92% maximal renal tubular reabsorption but did not define the conditions of this study. All patients had normal serum phosphate. The human manifestation of loss of Npt2b function contrasts sharply with the embryonic lethality of the Npt2b null mouse and suggests divergent embryonic functions for Npt2b in mice and humans.

The ductal cells demonstrate apical Npt2b expression in human salivary glands, whereas the acinar cells exhibit predominantly basolateral expression, suggesting phosphate secretion by the acini and phosphate reabsorption by the ducts (77). These findings have formed the basis for the development of a phosphate binder in chewing gum form. Npt2b is highly expressed in lactating breast tissue and may contribute to the relatively low phosphate content of human milk compared with cow milk (78). Npt2b is expressed on the surface of several cancers including breast, ovarian, renal, and lung and is being investigated as a potential therapeutic target for ovarian and breast cancer (79,80).

Npt2c

Npt2c (NaPi- IIc, SLC34A3) is the most recently described member of the type II sodium phosphate cotransporters, with expression limited exclusively to the apical membrane of the proximal renal tubule (81). Early studies demonstrated age dependent expression in rodents with the highest expression in weanling animals and regulation by dietary phosphate and parathyroid hormone. Mice homozygous for the disrupted Npt2c gene (Npt2c−/−) exhibit hypercalcemia, hypercalciuria, and increased plasma 1,25-dihydroxyvitamin D3 levels, but not hypophosphatemia, hyperphosphaturia, renal calcification, rickets, or osteomalacia (82). Sodium phosphate cotransport in renal brush border membrane vesicles is not decreased in Npt2c KO mice. Npt2c seems to have only a minor role in renal Pi reabsorption in rodents. Although Npt2c KO mice do not exhibit hypophosphatemia, plasma levels of FGF23 and FGF23 immunoreactivity in the osteocytes of Npt2c KO mice are decreased compared with wild-type mice, suggesting that Npt2c is necessary for regulation of the vitamin D/FGF23 axis.

In contrast to the relatively benign effects of loss of function of Npt2c in mice, recent studies identified a mutation of the Npt2c (Na/Pi-IIc, SCL34A3) transporter gene as the cause of the human disease, hereditary hypophosphatemic rickets with hypercalciuria (HHRH). This autosomal recessive disorder is characterized by hypophosphatemia, renal Pi wasting, increased serum 1,25 dihydroxyvitamin D3 concentrations, hypercalciuria, rickets, and osteomalacia (83–88). A genome-wide scan combined with homozygosity mapping using DNA from 10 patients with HHRH (83) identified a single nucleotide deletion (c.228delC) in all individuals in the initial cohort affected with HHRH. A variety of mutations including compound heterozygous deletion and missense mutations in Npt2c have been identified in other families with HHRH. Pi transport studies in a Xenopus oocyte system revealed that NPT2c gene mutations significantly decreased Na+-dependent Pi transport activity (88). These observations suggest that NPT2c has an important role in renal Pi reabsorption and bone mineralization, and that it may be a key determinant of plasma Pi concentration in humans. Segawa et al. compared biochemical findings in Npt2a null, Npt2c null, and double null animals to assess the relative importance of Npt2a and Npt2c (89). The animals lacking both transporters exhibited severe hypophosphatemia, hypercalciuria, and rickets, similar to that seen in HHRH. A high Pi diet reversed the bone abnormalities in the double null animals, as in HHRH. This study showed that in mice Npt2a and Npt2c have independent roles in the regulation of plasma Pi and bone mineralization.

As noted for the Npt2a and Npt2b knockout mice, absence of Npt2c produces a different phenotype in mice compared with humans. Whereas Npt2a and Npt2c have clearly nonredundant roles in mouse phosphate homeostasis, the similarity of the double knockout to the clinical presentation of HHRH suggests that the function of Npt2a and Npt2c may be interdependent in humans. This provocative suggestion has yet to be investigated in human participants.

Type III Sodium Phosphate Cotransporters

Type III sodium phosphate cotransporters, PiT1 and PiT2, are highly conserved, high-affinity phosphate transporters with broad organ expression, which were initially described as viral receptors, Glvr-1 and Ram-1 (1,90). The major clue to their potential function as phosphate transporters derived from their similarity to the fungal transporter, Pho-4+. These proteins express little homology to either type I or type II sodium phosphate cotransporters. Despite the redundancy in their amino acid sequences, PiT1 and PiT2 possess nonredundant functions. Very little information on the roles of these proteins in human physiology is available.

PiT1

Rodent studies show the strongest PiT1 (Glvr-1, SLC20A1) mRNA expression in bone marrow and brain but wide distribution in multiple organs including kidney, thymus, lung, liver, and heart (91). Deletion of PiT1 expression in mouse results in fetal demise due to failure of liver development (92,93). Although adult liver expresses little PiT1, fetal liver expresses very high levels of PiT1. In adult animals, partial hepatectomy results in a marked increase in PiT1 expression during liver regeneration. Interestingly, PiT2 expression doubled in the PiT1-deficient animals but could not rescue them, emphasizing the nonredundant nature of their respective roles. Studies in mouse distal collecting tubule cells did suggest a role for both PiT1 and PiT2 in distal phosphate reabsorption (94). PiT1 and PiT2 have been identified in human salivary glands (75).

A number of studies demonstrate a role for PiT1 in osteoblast- and chondrocyte-mediated mineralization (95–97). PiT1 expressed on matrix vesicles derived from the parent cell provides phosphate needed for mineralization. A potential role for PiT1 in the development of medial vascular calcification seen in CKD, diabetes, and aging has been suggested on the basis of multiple animal studies (98–100). Factors that enhance smooth muscle calcification such as prolonged exposure to high calcium, BMP2, and PDGF increase PiT1 expression. Inhibition of PiT1 expression results in decreased smooth muscle calcification in response to those stimuli. A role for PiT1 in human vascular calcification is supported by the finding that patients with Werner syndrome show enhanced expression of PiT1 at sites of vascular calcification (101).

PiT1 may play a critical role in regulation of apoptosis and cell proliferation, independent of its transport function (102–104). In human cancer cell lines, inhibition of PiT1 expression decreased cell proliferation and tumor formation. Salaun et al. also demonstrated that PiT1 but not PiT2 deficiency sensitized HeLa cells to TNF-induced apoptosis. PiT1 deficient HeLa cell proliferation was rescued by transfection of a transport-deficient PiT1 construct (104).

PiT2

Expression of PiT2 (Ram-1, SLC20A2) mRNA in rodents is highest in liver, heart, and brain but is also seen in kidney, thymus, lung, bone, and muscle. A PiT2-deficient mouse has not been described. PiT2 is expressed on the apical membrane of mouse proximal renal tubule cells and likely is responsible for at least a small percentage of phosphate reabsorption (105,106). Its expression increases in the Npt2a-deficient animal, although it is not able to rescue the phenotype entirely. As with PiT1, the transport and viral receptor functions of PiT2 can be dissociated (107). Interestingly, the oligomeric organization of PiT2 on the cell surface can respond to changes in ambient phosphate, suggesting that PiT2 oligomers may function as phosphate sensors. An association was recently described between PiT2 mutations and familial idiopathic basal ganglia calcification (107).

Summary

An emerging picture of the functions of the sodium phosphate cotransporters offers some opportunities for hypothesis generation with regard to the contributions of each of them to human physiology and pathophysiology. Type I transporters, although upregulated under pathophysiologic conditions of severe phosphate deprivation, play a more important role in the metabolism of uric acid and organic ions. The type II transporters on transepithelial transporting tissue clearly are the major contributors to phosphate homeostasis. Type III transporters with their ubiquitous expression, like the type I transporters, may make some contribution to phosphate homeostasis under pathophysiologic conditions but seem to play a more important role in non-epithelial cell phosphate transport, the mineralization process, and inflammation. Through intensive investigation in cell and animal models, paradigms of regulation of sodium phosphate cotransporter expression and function with respect to tissue, age, and sex are emerging. However, we are simultaneously discovering that significant species variability exists and application of knowledge from those models to human physiology and pathophysiology may be limited.

Disclosures

None.

Acknowledgments

E.L. is funded by a grant from the VA Merit Review Board.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2012 by the American Society of Nephrology

References

  1. ↵
    1. Forster I,
    2. Hernando N,
    3. Sorribas V,
    4. Werner A
    : Phosphate transporters in renal, gastrointestinal, and other tissues. Adv Chronic Kidney Dis 18: 63–76, 2011pmid:21406290
    OpenUrlCrossRefPubMed
  2. ↵
    1. Werner A,
    2. Moore ML,
    3. Mantei N,
    4. Biber J,
    5. Semenza G,
    6. Murer H
    : Cloning and expression of cDNA for a Na/Pi cotransport system of kidney cortex. Proc Natl Acad Sci USA 88: 9608–9612, 1991pmid:1946375
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Chong SS,
    2. Kristjansson K,
    3. Zoghbi HY,
    4. Hughes MR
    : Molecular cloning of the cDNA encoding a human renal sodium phosphate transport protein and its assignment to chromosome 6p21.3-p23. Genomics 18: 355–359, 1993pmid:8288239
    OpenUrlCrossRefPubMed
    1. Chong SS,
    2. Kozak CA,
    3. Liu L,
    4. Kristjansson K,
    5. Dunn ST,
    6. Bourdeau JE,
    7. Hughes MR
    : Cloning, genetic mapping, and expression analysis of a mouse renal sodium-dependent phosphate cotransporter. Am J Physiol 268: F1038–F1045, 1995pmid:7611445
    OpenUrlPubMed
  4. ↵
    1. Soumounou Y,
    2. Gauthier C,
    3. Tenenhouse HS
    : Murine and human type I Na-phosphate cotransporter genes: Structure and promoter activity. Am J Physiol Renal Physiol 281: F1082–F1091, 2001pmid:11704559
    OpenUrlCrossRefPubMed
  5. ↵
    1. Biber J,
    2. Custer M,
    3. Werner A,
    4. Kaissling B,
    5. Murer H
    : Localization of NaPi-1, a Na/Pi cotransporter, in rabbit kidney proximal tubules. II. Localization by immunohistochemistry. Pflugers Arch 424: 210–215, 1993pmid:8414908
    OpenUrlCrossRefPubMed
  6. ↵
    1. Busch AE,
    2. Schuster A,
    3. Waldegger S,
    4. Wagner CA,
    5. Zempel G,
    6. Broer S,
    7. Biber J,
    8. Murer H,
    9. Lang F
    : Expression of a renal type I sodium/phosphate transporter (NaPi-1) induces a conductance in Xenopus oocytes permeable for organic and inorganic anions. Proc Natl Acad Sci USA 93: 5347–5351, 1996
    1. Bröer S,
    2. Schuster A,
    3. Wagner CA,
    4. Bröer A,
    5. Forster I,
    6. Biber J,
    7. Murer H,
    8. Werner A,
    9. Lang F,
    10. Busch AE
    : Chloride conductance and Pi transport are separate functions induced by the expression of NaPi-1 in Xenopus oocytes. J Membr Biol 164: 71–77, 1998pmid:9636245
    OpenUrlCrossRefPubMed
  7. ↵
    1. Reimer RJ,
    2. Edwards RH
    : Organic anion transport is the primary function of the SLC17/type I phosphate transporter family. Pflugers Arch 447: 629–635, 2004pmid:12811560
    OpenUrlCrossRefPubMed
  8. ↵
    1. Uchino H,
    2. Tamai I,
    3. Yabuuchi H,
    4. China K,
    5. Miyamoto K,
    6. Takeda E,
    7. Tsuji A
    : Faropenem transport across the renal epithelial luminal membrane via inorganic phosphate transporter Npt1. Antimicrob Agents Chemother 44: 574–577, 2000pmid:10681320
    OpenUrlAbstract/FREE Full Text
    1. Uchino H,
    2. Tamai I,
    3. Yamashita K,
    4. Minemoto Y,
    5. Sai Y,
    6. Yabuuchi H,
    7. Miyamoto K,
    8. Takeda E,
    9. Tsuji A
    : p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 270: 254–259, 2000pmid:10733936
    OpenUrlCrossRefPubMed
    1. Urano W,
    2. Taniguchi A,
    3. Anzai N,
    4. Inoue E,
    5. Kanai Y,
    6. Yamanaka M,
    7. Endou H,
    8. Kamatani N,
    9. Yamanaka H
    : Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 69: 1232–1234, 2010pmid:19556210
    OpenUrlAbstract/FREE Full Text
    1. Iharada M,
    2. Miyaji T,
    3. Fujimoto T,
    4. Hiasa M,
    5. Anzai N,
    6. Omote H,
    7. Moriyama Y
    : Type 1 sodium-dependent phosphate transporter (SLC17A1 protein) is a Cl(-)-dependent urate exporter. J Biol Chem 285: 26107–26113, 2010pmid:20566650
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Ichida K
    : What lies behind serum urate concentration? Insights from genetic and genomic studies. Genome Med 1: 118, 2009
  10. ↵
    1. Yabuuchi H,
    2. Tamai I,
    3. Morita K,
    4. Kouda T,
    5. Miyamoto K,
    6. Takeda E,
    7. Tsuji A
    : Hepatic sinusoidal membrane transport of anionic drugs mediated by anion transporter Npt1. J Pharmacol Exp Ther 286: 1391–1396, 1998pmid:9732402
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Segawa H, Sawai Y, Tominaga R, Hanabusa E, Kuwahara S, Aranami F, Furutani J, Kaneko I, Koroiwa Y, Kusuhara H, Sugiyama Y, Miyamoto K: Inorganic phosphate homeostasis in the type I Na/Pi co-transporter (NPT1) null mice. Presented at the 42nd Annual Meeting of the American Society of Nephrology, Renal Week 2009, San Diego, CA, October 27–November 1, 2009
  12. ↵
    1. Dehghan A,
    2. Köttgen A,
    3. Yang Q,
    4. Hwang SJ,
    5. Kao WL,
    6. Rivadeneira F,
    7. Boerwinkle E,
    8. Levy D,
    9. Hofman A,
    10. Astor BC,
    11. Benjamin EJ,
    12. van Duijn CM,
    13. Witteman JC,
    14. Coresh J,
    15. Fox CS
    : Association of three genetic loci with uric acid concentration and risk of gout: A genome-wide association study. Lancet 372: 1953–1961, 2008pmid:18834626
    OpenUrlCrossRefPubMed
    1. Stark K,
    2. Reinhard W,
    3. Grassl M,
    4. Erdmann J,
    5. Schunkert H,
    6. Illig T,
    7. Hengstenberg C
    : Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE 4: e7729, 2009pmid:19890391
    OpenUrlCrossRefPubMed
    1. Brandstätter A,
    2. Lamina C,
    3. Kiechl S,
    4. Hunt SC,
    5. Coassin S,
    6. Paulweber B,
    7. Kramer F,
    8. Summerer M,
    9. Willeit J,
    10. Kedenko L,
    11. Adams TD,
    12. Kronenberg F
    : Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis 210: 474–478, 2010pmid:20053405
    OpenUrlCrossRefPubMed
  13. ↵
    1. Polasek O,
    2. Jeroncić I,
    3. Mulić R,
    4. Klismanic Z,
    5. Pehlić M,
    6. Zemunik T,
    7. Kolcić I
    : Common variants in SLC17A3 gene affect intra-personal variation in serum uric acid levels in longitudinal time series. Croat Med J 51: 32–39, 2010pmid:20162743
    OpenUrlCrossRefPubMed
  14. ↵
    1. Jutabha P,
    2. Anzai N,
    3. Kitamura K,
    4. Taniguchi A,
    5. Kaneko S,
    6. Yan K,
    7. Yamada H,
    8. Shimada H,
    9. Kimura T,
    10. Katada T,
    11. Fukutomi T,
    12. Tomita K,
    13. Urano W,
    14. Yamanaka H,
    15. Seki G,
    16. Fujita T,
    17. Moriyama Y,
    18. Yamada A,
    19. Uchida S,
    20. Wempe MF,
    21. Endou H,
    22. Sakurai H
    : Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 285: 35123–35132, 2010pmid:20810651
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Melis D,
    2. Havelaar AC,
    3. Verbeek E,
    4. Smit GP,
    5. Benedetti A,
    6. Mancini GM,
    7. Verheijen F
    : NPT4, a new microsomal phosphate transporter: Mutation analysis in glycogen storage disease type Ic. J Inherit Metab Dis 27: 725–733, 2004pmid:15505377
    OpenUrlCrossRefPubMed
  16. ↵
    1. Magagnin S,
    2. Werner A,
    3. Markovich D,
    4. Sorribas V,
    5. Stange G,
    6. Biber J,
    7. Murer H
    : Expression cloning of human and rat renal cortex Na/Pi cotransport. Proc Natl Acad Sci USA 90: 5979–5983, 1993pmid:8327470
    OpenUrlAbstract/FREE Full Text
    1. Sorribas V,
    2. Markovich D,
    3. Hayes G,
    4. Stange G,
    5. Forgo J,
    6. Biber J,
    7. Murer H
    : Cloning of a Na/Pi cotransporter from opossum kidney cells. J Biol Chem 269: 6615–6621, 1994pmid:7509808
    OpenUrlAbstract/FREE Full Text
    1. Helps C,
    2. Murer H,
    3. McGivan J
    : Cloning, sequence analysis and expression of the cDNA encoding a sodium-dependent phosphate transporter from the bovine renal epithelial cell line NBL-1. Eur J Biochem 228: 927–930, 1995pmid:7737195
    OpenUrlPubMed
    1. Verri T,
    2. Markovich D,
    3. Perego C,
    4. Norbis F,
    5. Stange G,
    6. Sorribas V,
    7. Biber J,
    8. Murer H
    : Cloning of a rabbit renal Na-Pi cotransporter, which is regulated by dietary phosphate. Am J Physiol 268: F626–F633, 1995pmid:7733319
    OpenUrlPubMed
  17. ↵
    1. Werner A,
    2. Murer H,
    3. Kinne RK
    : Cloning and expression of a renal Na-Pi cotransport system from flounder. Am J Physiol 267: F311–F317, 1994
    1. Gupta A,
    2. Miyauchi A,
    3. Fujimori A,
    4. Hruska KA
    : Phosphate transport in osteoclasts: A functional and immunochemical characterization. Kidney Int 49: 968–974, 1996pmid:8691746
    OpenUrlCrossRefPubMed
    1. Gupta A,
    2. Guo X-L,
    3. Alvarez UM,
    4. Hruska KA
    : Regulation of sodium-dependent phosphate transport in osteoclasts. J Clin Invest 100: 538–549, 1997pmid:9239400
    OpenUrlCrossRefPubMed
  18. ↵
    1. Khadeer MA,
    2. Tang Z,
    3. Tenenhouse HS,
    4. Eiden MV,
    5. Murer H,
    6. Hernando N,
    7. Weinman EJ,
    8. Chellaiah MA,
    9. Gupta A
    : Na+-dependent phosphate transporters in the murine osteoclast: Cellular distribution and protein interactions. Am J Physiol Cell Physiol 284: C1633–C1644, 2003pmid:12606316
    OpenUrlCrossRefPubMed
  19. ↵
    1. Tenenhouse HS,
    2. Roy S,
    3. Martel J,
    4. Gauthier C
    : Differential expression, abundance, and regulation of Na+-phosphate cotransporter genes in murine kidney. Am J Physiol 275: F527–F534, 1998pmid:9755124
    OpenUrlPubMed
  20. ↵
    1. Beck L,
    2. Karaplis AC,
    3. Amizuka N,
    4. Hewson AS,
    5. Ozawa H,
    6. Tenenhouse HS
    : Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA 95: 5372–5377, 1998pmid:9560283
    OpenUrlAbstract/FREE Full Text
    1. Hoag HM,
    2. Martel J,
    3. Gauthier C,
    4. Tenenhouse HS
    : Effects of Npt2 gene ablation and low-phosphate diet on renal Na(+)/phosphate cotransport and cotransporter gene expression. J Clin Invest 104: 679–686, 1999pmid:10491403
    OpenUrlCrossRefPubMed
    1. Tenenhouse HS
    : Regulation of phosphorus homeostasis by the type IIa Na/phosphate cotransporter. Annu Rev Nutr 25: 197–214, 2005pmid:16011465
    OpenUrlCrossRefPubMed
    1. Tenenhouse HS
    : Phosphate transport: Molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 103: 572–577, 2007pmid:17270430
    OpenUrlCrossRefPubMed
  21. ↵
    1. Blaine J,
    2. Weinman EJ,
    3. Cunningham R
    : The regulation of renal phosphate transport. Adv Chronic Kidney Dis 18: 77–84, 2011pmid:21406291
    OpenUrlCrossRefPubMed
  22. ↵
    1. Cheng X,
    2. Klaassen CD
    : Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. Drug Metab Dispos 37: 2178–2185, 2009pmid:19679677
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Kaneko I, Segawa H, Furutani J, Kuwahara S, Aranami F, Hanabusa E, Tominaga R, Giral H, Caldas Y, Levi M, Kato S, Miyamoto K: Hypophosphatemia in vitamin D receptor null mice: Effect of rescue diet on the developmental changes in renal Na+-dependent phosphate cotransporters. Pflugers Arch 461: 77–90, 2011
  24. ↵
    1. Tenenhouse HS,
    2. Martel J,
    3. Gauthier C,
    4. Zhang MY,
    5. Portale AA
    : Renal expression of the sodium/phosphate cotransporter gene, Npt2, is not required for regulation of renal 1 alpha-hydroxylase by phosphate. Endocrinology 142: 1124–1129, 2001pmid:11181527
    OpenUrlCrossRefPubMed
  25. ↵
    Lederer ED, Sohi SS, Bhatnagar KP, Gunn RB: Age-Related Expression of the Type II Sodium-Phosphate Cotransporter in the Human Kidney, Bethesda, MD, Federation of American Societies for Experimental Biology, 2001
  26. ↵
    1. Alizadeh Naderi AS,
    2. Reilly RF
    : Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 6: 657–665, 2010pmid:20924400
    OpenUrlCrossRefPubMed
  27. ↵
    1. Cai Q,
    2. Hodgson SF,
    3. Kao PC,
    4. Lennon VA,
    5. Klee GG,
    6. Zinsmiester AR,
    7. Kumar R
    : Brief report: Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330: 1645–1649, 1994pmid:8177270
    OpenUrlCrossRefPubMed
    1. Kumar R
    : Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 27: 333–338, 2000pmid:10962341
    OpenUrlPubMed
    1. White KE,
    2. Evans WE,
    3. O'Riordan JL,
    4. Speer MC,
    5. Econs MJ,
    6. Lorenz-Depiereux B,
    7. Grabowski M,
    8. Meitinger T,
    9. Strom TM,
    10. ADHR Consortium
    : Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26: 345–348, 2000pmid:11062477
    OpenUrlCrossRefPubMed
    1. Razzaque MS
    : The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5: 611–619, 2009pmid:19844248
    OpenUrlCrossRefPubMed
  28. ↵
    1. Amatschek S,
    2. Haller M,
    3. Oberbauer R
    : Renal phosphate handling in human—what can we learn from hereditary hypophosphataemias? Eur J Clin Invest 40: 552–560, 2010pmid:20412291
    OpenUrlCrossRefPubMed
  29. ↵
    1. Topaz O,
    2. Shurman DL,
    3. Bergman R,
    4. Indelman M,
    5. Ratajczak P,
    6. Mizrachi M,
    7. Khamaysi Z,
    8. Behar D,
    9. Petronius D,
    10. Friedman V,
    11. Zelikovic I,
    12. Raimer S,
    13. Metzker A,
    14. Richard G,
    15. Sprecher E
    : Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36: 579–581, 2004pmid:15133511
    OpenUrlCrossRefPubMed
    1. Benet-Pagès A,
    2. Orlik P,
    3. Strom TM,
    4. Lorenz-Depiereux B
    : An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14: 385–390, 2005pmid:15590700
    OpenUrlCrossRefPubMed
  30. ↵
    1. Sprecher E
    : Familial tumoral calcinosis: From characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol 130: 652–660, 2010pmid:19865099
    OpenUrlCrossRefPubMed
  31. ↵
    1. Lundquist P,
    2. Murer H,
    3. Biber J
    : Type II Na+-Pi cotransporters in osteoblast mineral formation: Regulation by inorganic phosphate. Cell Physiol Biochem 19: 43–56, 2007pmid:17310099
    OpenUrlCrossRefPubMed
  32. ↵
    1. Gupta A,
    2. Tenenhouse HS,
    3. Hoag HM,
    4. Wang D,
    5. Khadeer MA,
    6. Namba N,
    7. Feng X,
    8. Hruska KA
    : Identification of the type II Na(+)-Pi cotransporter (Npt2) in the osteoclast and the skeletal phenotype of Npt2-/- mice. Bone 29: 467–476, 2001pmid:11704500
    OpenUrlPubMed
  33. ↵
    1. Bockman RS
    : First it’s rickets, then it’s not the sodium-phosphate transporter 2a knockout mystery. Endocrinology 151: 4599–4601, 2010pmid:20858767
    OpenUrlCrossRefPubMed
  34. ↵
    Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, Hulin P, Benqué-Blanchet F, Silve C, Grandchamp B, Friedlander G: Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 374: 983–991, 2002
    OpenUrl
  35. ↵
    1. Lapointe J-Y,
    2. Tessier J,
    3. Paquette Y,
    4. Wallendorff B,
    5. Coady MJ,
    6. Pichette V,
    7. Bonnardeaux A
    : NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 69: 2261–2267, 2006pmid:16688119
    OpenUrlCrossRefPubMed
  36. ↵
    1. Khan SR,
    2. Glenton PA
    : Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter. Am J Physiol Renal Physiol 294: F1109–F1115, 2008pmid:18337544
    OpenUrlCrossRefPubMed
    1. Khan SR
    : Nephrocalcinosis in animal models with and without stones. Urol Res 38: 429–438, 2010pmid:20658131
    OpenUrlCrossRefPubMed
    1. Khan SR,
    2. Canales BK
    : Ultrastructural investigation of crystal deposits in Npt2a knockout mice: Are they similar to human Randall’s plaques? J Urol 186: 1107–1113, 2011pmid:21784483
    OpenUrlCrossRefPubMed
    1. Iwaki T,
    2. Sandoval-Cooper MJ,
    3. Tenenhouse HS,
    4. Castellino FJ
    : A missense mutation in the sodium phosphate co-transporter Slc34a1 impairs phosphate homeostasis. J Am Soc Nephrol 19: 1753–1762, 2008pmid:18550648
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Magen D,
    2. Berger L,
    3. Coady MJ,
    4. Ilivitzki A,
    5. Militianu D,
    6. Tieder M,
    7. Selig S,
    8. Lapointe JY,
    9. Zelikovic I,
    10. Skorecki K
    : A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 362: 1102–1109, 2010pmid:20335586
    OpenUrlCrossRefPubMed
  38. ↵
    1. Tieder M,
    2. Arie R,
    3. Modai D,
    4. Samuel R,
    5. Weissgarten J,
    6. Liberman UA
    : Elevated serum 1,25-dihydroxyvitamin D concentrations in siblings with primary Fanconi’s syndrome. N Engl J Med 319: 845–849, 1988pmid:2842681
    OpenUrlCrossRefPubMed
  39. ↵
    1. Brazy PC,
    2. Gullans SR,
    3. Mandel LJ,
    4. Dennis VW
    : Metabolic requirement for inorganic phosphate by the rabbit proximal tubule. J Clin Invest 70: 53–62, 1982pmid:7085888
    OpenUrlCrossRefPubMed
  40. ↵
    1. Kestenbaum B,
    2. Glazer NL,
    3. Köttgen A,
    4. Felix JF,
    5. Hwang SJ,
    6. Liu Y,
    7. Lohman K,
    8. Kritchevsky SB,
    9. Hausman DB,
    10. Petersen AK,
    11. Gieger C,
    12. Ried JS,
    13. Meitinger T,
    14. Strom TM,
    15. Wichmann HE,
    16. Campbell H,
    17. Hayward C,
    18. Rudan I,
    19. de Boer IH,
    20. Psaty BM,
    21. Rice KM,
    22. Chen YD,
    23. Li M,
    24. Arking DE,
    25. Boerwinkle E,
    26. Coresh J,
    27. Yang Q,
    28. Levy D,
    29. van Rooij FJ,
    30. Dehghan A,
    31. Rivadeneira F,
    32. Uitterlinden AG,
    33. Hofman A,
    34. van Duijn CM,
    35. Shlipak MG,
    36. Kao WH,
    37. Witteman JC,
    38. Siscovick DS,
    39. Fox CS
    : Common genetic variants associate with serum phosphorus concentration. J Am Soc Nephrol 21: 1223–1232, 2010pmid:20558539
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Köttgen A,
    2. Pattaro C,
    3. Böger CA,
    4. Fuchsberger C,
    5. Olden M,
    6. Glazer NL,
    7. Parsa A,
    8. Gao X,
    9. Yang Q,
    10. Smith AV,
    11. O’Connell JR,
    12. Li M,
    13. Schmidt H,
    14. Tanaka T,
    15. Isaacs A,
    16. Ketkar S,
    17. Hwang SJ,
    18. Johnson AD,
    19. Dehghan A,
    20. Teumer A,
    21. Paré G,
    22. Atkinson EJ,
    23. Zeller T,
    24. Lohman K,
    25. Cornelis MC,
    26. Probst-Hensch NM,
    27. Kronenberg F,
    28. Tönjes A,
    29. Hayward C,
    30. Aspelund T,
    31. Eiriksdottir G,
    32. Launer LJ,
    33. Harris TB,
    34. Rampersaud E,
    35. Mitchell BD,
    36. Arking DE,
    37. Boerwinkle E,
    38. Struchalin M,
    39. Cavalieri M,
    40. Singleton A,
    41. Giallauria F,
    42. Metter J,
    43. de Boer IH,
    44. Haritunians T,
    45. Lumley T,
    46. Siscovick D,
    47. Psaty BM,
    48. Zillikens MC,
    49. Oostra BA,
    50. Feitosa M,
    51. Province M,
    52. de Andrade M,
    53. Turner ST,
    54. Schillert A,
    55. Ziegler A,
    56. Wild PS,
    57. Schnabel RB,
    58. Wilde S,
    59. Munzel TF,
    60. Leak TS,
    61. Illig T,
    62. Klopp N,
    63. Meisinger C,
    64. Wichmann HE,
    65. Koenig W,
    66. Zgaga L,
    67. Zemunik T,
    68. Kolcic I,
    69. Minelli C,
    70. Hu FB,
    71. Johansson A,
    72. Igl W,
    73. Zaboli G,
    74. Wild SH,
    75. Wright AF,
    76. Campbell H,
    77. Ellinghaus D,
    78. Schreiber S,
    79. Aulchenko YS,
    80. Felix JF,
    81. Rivadeneira F,
    82. Uitterlinden AG,
    83. Hofman A,
    84. Imboden M,
    85. Nitsch D,
    86. Brandstätter A,
    87. Kollerits B,
    88. Kedenko L,
    89. Mägi R,
    90. Stumvoll M,
    91. Kovacs P,
    92. Boban M,
    93. Campbell S,
    94. Endlich K,
    95. Völzke H,
    96. Kroemer HK,
    97. Nauck M,
    98. Völker U,
    99. Polasek O,
    100. Vitart V,
    101. Badola S,
    102. Parker AN,
    103. Ridker PM,
    104. Kardia SL,
    105. Blankenberg S,
    106. Liu Y,
    107. Curhan GC,
    108. Franke A,
    109. Rochat T,
    110. Paulweber B,
    111. Prokopenko I,
    112. Wang W,
    113. Gudnason V,
    114. Shuldiner AR,
    115. Coresh J,
    116. Schmidt R,
    117. Ferrucci L,
    118. Shlipak MG,
    119. van Duijn CM,
    120. Borecki I,
    121. Krämer BK,
    122. Rudan I,
    123. Gyllensten U,
    124. Wilson JF,
    125. Witteman JC,
    126. Pramstaller PP,
    127. Rettig R,
    128. Hastie N,
    129. Chasman DI,
    130. Kao WH,
    131. Heid IM,
    132. Fox CS
    : New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376–384, 2010pmid:20383146
    OpenUrlCrossRefPubMed
  42. ↵
    1. Kendrick J,
    2. Kestenbaum B,
    3. Chonchol M
    : Phosphate and cardiovascular disease. Adv Chronic Kidney Dis 18: 113–119, 2011pmid:21406296
    OpenUrlCrossRefPubMed
  43. ↵
    1. Hilfiker H,
    2. Hattenhauer O,
    3. Traebert M,
    4. Forster I,
    5. Murer H,
    6. Biber J
    : Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA 95: 14564–14569, 1998pmid:9826740
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Traebert M,
    2. Hattenhauer O,
    3. Murer H,
    4. Kaissling B,
    5. Biber J
    : Expression of type II Na-Pi cotransporter in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 277: L868–L873, 1999
    OpenUrlPubMed
  45. ↵
    1. Onishi T,
    2. Okawa R,
    3. Ogawa T,
    4. Shintani S,
    5. Ooshima T,
    6. Wagenfeld A,
    7. Lang F,
    8. Cooper TG
    : Phex mutation causes the reduction of npt2b mRNA in teeth. J Dent Res 86: 158–162, 2007pmid:17251516
    OpenUrlCrossRefPubMed
    1. Huber K,
    2. Muscher A,
    3. Breves G
    : Sodium-dependent phosphate transport across the apical membrane of alveolar epithelium in caprine mammary gland. Comp Biochem Physiol A Mol Integr Physiol 146: 215–222, 2007pmid:17137815
    OpenUrlCrossRefPubMed
    1. Frei P,
    2. Gao B,
    3. Hagenbuch B,
    4. Mate A,
    5. Biber J,
    6. Murer H,
    7. Meier PJ,
    8. Stieger B
    : Identification and localization of sodium-phosphate cotransporters in hepatocytes and cholangiocytes of rat liver. Am J Physiol Gastrointest Liver Physiol 288: G771–G778, 2005pmid:15564340
    OpenUrlCrossRefPubMed
  46. ↵
    1. Shibasaki Y,
    2. Etoh N,
    3. Hayasaka M,
    4. Takahashi MO,
    5. Kakitani M,
    6. Yamashita T,
    7. Tomizuka K,
    8. Hanaoka K
    : Targeted deletion of the tybe IIb Na(+)-dependent Pi-co-transporter, NaPi-IIb, results in early embryonic lethality. Biochem Biophys Res Commun 381: 482–486, 2009pmid:19233126
    OpenUrlCrossRefPubMed
  47. ↵
    1. Sabbagh Y,
    2. O’Brien SP,
    3. Song W,
    4. Boulanger JH,
    5. Stockmann A,
    6. Arbeeny C,
    7. Schiavi SC
    : Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20: 2348–2358, 2009pmid:19729436
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Xu H,
    2. Bai L,
    3. Collins JF,
    4. Ghishan FK
    : Molecular cloning, functional characterization, tissue distribution, and chromosomal localization of a human, small intestinal sodium-phosphate (Na+-Pi) transporter (SLC34A2). Genomics 62: 281–284, 1999pmid:10610722
    OpenUrlCrossRefPubMed
  49. ↵
    1. Feild JA,
    2. Zhang L,
    3. Brun KA,
    4. Brooks DP,
    5. Edwards RM
    : Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine. Biochem Biophys Res Commun 258: 578–582, 1999pmid:10329428
    OpenUrlCrossRefPubMed
    1. Homann V,
    2. Rosin-Steiner S,
    3. Stratmann T,
    4. Arnold WH,
    5. Gaengler P,
    6. Kinne RK
    : Sodium-phosphate cotransporter in human salivary glands: molecular evidence for the involvement of NPT2b in acinar phosphate secretion and ductal phosphate reabsorption. Arch Oral Biol 50: 759–768, 2005pmid:15970207
    OpenUrlCrossRefPubMed
  50. ↵
    1. Corut A,
    2. Senyigit A,
    3. Ugur SA,
    4. Altin S,
    5. Ozcelik U,
    6. Calisir H,
    7. Yildirim Z,
    8. Gocmen A,
    9. Tolun A
    : Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 79: 650–656, 2006pmid:16960801
    OpenUrlCrossRefPubMed
  51. ↵
    Huqun, Izumi S, Miyazawa H, Ishii K, Uchiyama B, Ishida T, Tanaka S, Tazawa R, Fukuyama S, Tanaka T, Nagai Y, Yokote A, Takahashi H, Fukushima T, Kobayashi K, Chiba H, Nagata M, Sakamoto S, Nakata K, Takebayashi Y, Shimizu Y, Kaneko K, Shimizu M, Kanazawa M, Abe S, Inoue Y, Takenoshita S, Yoshimura K, Kudo K, Tachibana T, Nukiwa T, Hagiwara K: Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 175: 263–268, 2007
    OpenUrlCrossRefPubMed
  52. ↵
    1. Hess AF,
    2. Helman FD
    : The phosphatide and total phosphorus content of woman’s and cow’s milk. J Biol Chem 64: 193–202, 1925
  53. ↵
    1. Yin BW,
    2. Kiyamova R,
    3. Chua R,
    4. Caballero OL,
    5. Gout I,
    6. Gryshkova V,
    7. Bhaskaran N,
    8. Souchelnytskyi S,
    9. Hellman U,
    10. Filonenko V,
    11. Jungbluth AA,
    12. Odunsi K,
    13. Lloyd KO,
    14. Old LJ,
    15. Ritter G
    : Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun 8: 3–12, 2008pmid:18251464
    OpenUrlPubMed
  54. ↵
    1. Chen DR,
    2. Chien SY,
    3. Kuo SJ,
    4. Teng YH,
    5. Tsai HT,
    6. Kuo JH,
    7. Chung JG
    : SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer. Anticancer Res 30: 4135–4140, 2010pmid:21036732
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Ohkido I,
    2. Segawa H,
    3. Yanagida R,
    4. Nakamura M,
    5. Miyamoto K
    : Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflugers Arch 446: 106–115, 2003pmid:12690469
    OpenUrlCrossRefPubMed
  56. ↵
    1. Segawa H,
    2. Onitsuka A,
    3. Kuwahata M,
    4. Hanabusa E,
    5. Furutani J,
    6. Kaneko I,
    7. Tomoe Y,
    8. Aranami F,
    9. Matsumoto N,
    10. Ito M,
    11. Matsumoto M,
    12. Li M,
    13. Amizuka N,
    14. Miyamoto K
    : Type IIc sodium-dependent phosphate transporter regulates calcium metabolism. J Am Soc Nephrol 20: 104–113, 2009pmid:19056871
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Bergwitz C,
    2. Roslin NM,
    3. Tieder M,
    4. Loredo-Osti JC,
    5. Bastepe M,
    6. Abu-Zahra H,
    7. Frappier D,
    8. Burkett K,
    9. Carpenter TO,
    10. Anderson D,
    11. Garabedian M,
    12. Sermet I,
    13. Fujiwara TM,
    14. Morgan K,
    15. Tenenhouse HS,
    16. Juppner H
    : SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 78: 179–192, 2006pmid:16358214
    OpenUrlCrossRefPubMed
  58. ↵
    1. Ichikawa S,
    2. Sorenson AH,
    3. Imel EA,
    4. Friedman NE,
    5. Gertner JM,
    6. Econs MJ
    : Intronic deletions in the SLC34A3 gene cause hereditary hypophosphatemic rickets with hypercalciuria. J Clin Endocrinol Metab 91: 4022–4027, 2006pmid:16849419
    OpenUrlCrossRefPubMed
    1. Jaureguiberry G,
    2. Carpenter TO,
    3. Forman S,
    4. Jüppner H,
    5. Bergwitz C
    : A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol 295: F371–F379, 2008pmid:18480181
    OpenUrlCrossRefPubMed
    1. Kremke B,
    2. Bergwitz C,
    3. Ahrens W,
    4. Schütt S,
    5. Schumacher M,
    6. Wagner V,
    7. Holterhus PM,
    8. Jüppner H,
    9. Hiort O
    : Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications. Exp Clin Endocrinol Diabetes 117: 49–56, 2009pmid:18523928
    OpenUrlCrossRefPubMed
    1. Lorenz-Depiereux B,
    2. Benet-Pages A,
    3. Eckstein G,
    4. Tenenbaum-Rakover Y,
    5. Wagenstaller J,
    6. Tiosano D,
    7. Gershoni-Baruch R,
    8. Albers N,
    9. Lichtner P,
    10. Schnabel D,
    11. Hochberg Z,
    12. Strom TM
    : Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78: 193–201, 2006pmid:16358215
    OpenUrlCrossRefPubMed
    1. Yamamoto T,
    2. Michigami T,
    3. Aranami F,
    4. Segawa H,
    5. Yoh K,
    6. Nakajima S,
    7. Miyamoto K,
    8. Ozono K
    : Hereditary hypophosphatemic rickets with hypercalciuria: A study for the phosphate transporter gene type IIc and osteoblastic function. J Bone Miner Metab 25: 407–413, 2007pmid:17968493
    OpenUrlCrossRefPubMed
  59. ↵
    1. Segawa H,
    2. Onitsuka A,
    3. Furutani J,
    4. Kaneko I,
    5. Aranami F,
    6. Matsumoto N,
    7. Tomoe Y,
    8. Kuwahata M,
    9. Ito M,
    10. Matsumoto M,
    11. Li M,
    12. Amizuka N,
    13. Miyamoto K
    : Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 297: F671–F678, 2009pmid:19570882
    OpenUrlCrossRefPubMed
  60. ↵
    1. Kavanaugh MP,
    2. Kabat D
    : Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int 49: 959–963, 1996pmid:8691744
    OpenUrlCrossRefPubMed
  61. ↵
    1. Kavanaugh MP,
    2. Miller DG,
    3. Zhang W,
    4. Law W,
    5. Kozak SL,
    6. Kabat D,
    7. Miller AD
    : Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 91: 7071–7075, 1994pmid:8041748
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Festing MH,
    2. Speer MY,
    3. Yang H-Y,
    4. Giachelli CM
    : Generation of mouse conditional and null alleles of the type III sodium-dependent phosphate cotransporter PiT-1. Genesis 47: 858–863, 2009pmid:19882669
    OpenUrlPubMed
  63. ↵
    1. Coulombel L,
    2. Friedlander G
    : The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development. PLoS ONE 5: e9148, 2010pmid:20161774
    OpenUrlCrossRefPubMed
  64. ↵
    1. Tenenhouse HS,
    2. Gauthier C,
    3. Martel J,
    4. Gesek FA,
    5. Coutermarsh BA,
    6. Friedman PA
    : Na+ -phosphate cotransport in mouse distal convoluted tubule cells: Evidence for Glvr-1 and Ram-1 gene expression. J Bone Miner Res 13: 590–597, 1998pmid:9556059
    OpenUrlCrossRefPubMed
  65. ↵
    1. Palmer G,
    2. Bonjour J-P,
    3. Caverzasio J
    : Expression of a newly identified phosphate transporter/retrovirus receptor in human SaOS-2 osteoblast-like cells and its regulation by insulin-like growth factor I. Endocrinology 138: 5202–5209, 1997pmid:9389502
    OpenUrlCrossRefPubMed
  66. ↵
    1. Solomon DH,
    2. Wilkins RJ,
    3. Meredith D,
    4. Browning JA
    : Characterisation of inorganic phosphate transport in bovine articular chondrocytes. Cell Physiol Biochem 20: 99–108, 2007pmid:17595520
    OpenUrlPubMed
    1. Yoshiko Y,
    2. Candeliere GA,
    3. Maeda N,
    4. Aubin JE
    : Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization. Mol Cell Biol 27: 4465–4474, 2007pmid:17438129
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Villa-Bellosta R,
    2. Bogaert YE,
    3. Levi M,
    4. Sorribas V
    : Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 27: 1030–1036, 2007pmid:17322102
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Li X,
    2. Giachelli CM
    : Sodium-dependent phosphate cotransporters and vascular calcification. Curr Opin Nephrol Hypertens 16: 325–328, 2007pmid:17565274
    OpenUrlCrossRefPubMed
    1. Li X,
    2. Yang H-Y,
    3. Giachelli CM
    : Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98: 905–912, 2006pmid:16527991
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Honjo S,
    2. Yokote K,
    3. Fujimoto M,
    4. Takemoto M,
    5. Kobayashi K,
    6. Maezawa Y,
    7. Shimoyama T,
    8. Satoh S,
    9. Koshizaka M,
    10. Takada A,
    11. Irisuna H,
    12. Saito Y
    : Clinical outcome and mechanism of soft tissue calcification in Werner syndrome. Rejuvenation Res 11: 809–819, 2008pmid:18729813
    OpenUrlCrossRefPubMed
  70. ↵
    1. Denoyer D,
    2. Perek N,
    3. Jeune NL,
    4. Frere D,
    5. Sabido O,
    6. Clotagatide A,
    7. Dubois F
    : In vitro and in vivo evaluation of the influence of type III NaPi co-transporter activity during apoptosis on 99mTc-(V)DMSA uptake in the human leukaemic cell line U937. Eur J Nucl Med Mol Imaging 31: 1421–1427, 2004pmid:15205924
    OpenUrlPubMed
  71. ↵
    1. Beck L,
    2. Leroy C,
    3. Salaün C,
    4. Margall-Ducos G,
    5. Desdouets C,
    6. Friedlander G
    : Identification of a novel function of PiT1 critical for cell proliferation and independent of its phosphate transport activity. J Biol Chem 284: 31363–31374, 2009pmid:19726692
    OpenUrlAbstract/FREE Full Text
    1. Salaün C,
    2. Leroy C,
    3. Rousseau A,
    4. Boitez V,
    5. Beck L,
    6. Friedlander G
    : Identification of a novel transport-independent function of PiT1/SLC20A1 in the regulation of TNF-induced apoptosis. J Biol Chem 285: 34408–34418, 2010pmid:20817733
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Villa-Bellosta R,
    2. Ravera S,
    3. Sorribas V,
    4. Stange G,
    5. Levi M,
    6. Murer H,
    7. Biber J,
    8. Forster IC
    : The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. Am J Physiol Renal Physiol 296: F691–F699, 2009pmid:19073637
    OpenUrlCrossRefPubMed
  73. ↵
    1. Villa-Bellosta R,
    2. Sorribas V
    : Compensatory regulation of the sodium/phosphate cotransporters NaPi-IIc (SCL34A3) and Pit-2 (SLC20A2) during Pi deprivation and acidosis. Pflugers Arch 459: 499–508, 2010pmid:19841935
    OpenUrlCrossRefPubMed
  74. ↵
    1. Salaün C,
    2. Maréchal V,
    3. Heard JM
    : Transport-deficient Pit2 phosphate transporters still modify cell surface oligomers structure in response to inorganic phosphate. J Mol Biol 340: 39–47, 2004pmid:15184021
    OpenUrlCrossRefPubMed
  75. ↵
    1. Wang C,
    2. Li Y,
    3. Shi L,
    4. Ren J,
    5. Patti M,
    6. Wang T,
    7. de Oliveira JR,
    8. Sobrido MJ,
    9. Quintáns B,
    10. Baquero M,
    11. Cui X,
    12. Zhang XY,
    13. Wang L,
    14. Xu H,
    15. Wang J,
    16. Yao J,
    17. Dai X,
    18. Liu J,
    19. Zhang L,
    20. Ma H,
    21. Gao Y,
    22. Ma X,
    23. Feng S,
    24. Liu M,
    25. Wang QK,
    26. Forster IC,
    27. Zhang X,
    28. Liu JY
    : Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet 44: 254–256, 2012pmid:22327515
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 7 (7)
Clinical Journal of the American Society of Nephrology
Vol. 7, Issue 7
July 06, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Clinical Consequences of Mutations in Sodium Phosphate Cotransporters
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinical Consequences of Mutations in Sodium Phosphate Cotransporters
Eleanor Lederer, Ken-ichi Miyamoto
CJASN Jul 2012, 7 (7) 1179-1187; DOI: 10.2215/CJN.09090911

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Clinical Consequences of Mutations in Sodium Phosphate Cotransporters
Eleanor Lederer, Ken-ichi Miyamoto
CJASN Jul 2012, 7 (7) 1179-1187; DOI: 10.2215/CJN.09090911
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Type I Sodium Phosphate Cotransporters
    • Type II Sodium Phosphate Cotransporters
    • Type III Sodium Phosphate Cotransporters
    • Summary
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome
  • Recognition and Management of Resistant Hypertension
  • Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies
Show more In-Depth Review

Cited By...

  • Homeostasis, the Milieu Interieur, and the Wisdom of the Nephron
  • Evaluation of SLC20A2 mutations that cause idiopathic basal ganglia calcification in Japan
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire